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Tuberculosis (TB) remains a major threat to human health worldwide. The increasing incidence of 2 
non-tuberculous mycobacterial infections and particularly those produced by Mycobacterium avium 3 
has emphasized the need to develop new drugs. Additionally, high levels of natural drug resistance 4 
in non-tuberculous mycobacteria (NTM) and the emergence of multidrug-resistant (MDR) TB is of 5 
great concern. Antimicrobial peptides (AMPs) are antibiotics with broad-spectrum antimicrobial 6 
activity. The objective was to assess the activity of AMPs against Mycobacterium tuberculosis and 7 
M. avium clinical isolates. Minimum inhibitory concentrations (MIC) were determined using 8 
microtiter plates and the resazurin assay. Mastoparan and melittin showed the greatest activity against 9 
M. tuberculosis, while indolicidin had the lowest MIC against M. avium. In conclusion, AMPs could 10 
be alternatives for the treatment of mycobacterial infections. Further investigation of AMPs activity 11 
in combination and associated with conventional antibiotics and their loading into drug-delivery 12 
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Tuberculosis (TB) remains a major health problem worldwide and is one of the leading causes of 28 
death by a single infectious agent, that is, Mycobacterium tuberculosis. According to the World 29 
Health Organization in 2016 there were an estimated 10.4 million new TB cases and 1.6 million TB 30 
deaths [1]. Furthermore, the emergence of multidrug-resistant (MDR) TB and extensively drug-31 
resistant (XDR) TB has led to the need to develop new treatment options [2].  32 
Infections produced by nontuberculous mycobacteria (NTM) have dramatically increased in the last 33 
years, mainly in immunocompromised patients and individuals with pre-existing pulmonary diseases. 34 
Among these NTM, Mycobacterium avium is of note and is gaining increasingly more relevant 35 
clinical significance. The high levels of natural drug resistance of NTM lead to poor treatment 36 
outcomes requiring novel drug regimens and compounds [3].  37 
Antimicrobial peptides (AMPs) are powerful natural antibiotics produced by all life forms from 38 
microorganisms to humans [4-6]. AMPs tend to be relatively short (20-60 amino acid residues), 39 
amphipathic and positively charged. Four main structural AMPs classes have been defined: α-helix, 40 
β-hairpin, β-sheet, and linear, non α-helical [7]. In addition, several AMPs databases, such as the 41 
Antimicrobial Peptide Database (APD), Dragon Antimicrobial Peptide Database (DAMPD) and the 42 
database Linking Antimicrobial Peptide (LAMP) are available, providing comprehensive information 43 
about their antimicrobial activity and mechanisms of action [8, 7]. 44 
AMPs play an important role in the innate immune response and have the ability to modulate host 45 
defences. They promote pathogen clearance with their broad-spectrum antimicrobial activity against 46 
bacteria, viruses, parasites and fungi. Most AMPs target the cell wall by different modes of action, 47 
such as pore formation, thinning, altered curvature, localized perturbations and modified 48 
electrostatics [9]. Hence, the interaction between AMPs and the membrane may result in disruption 49 
of the bacterial membrane. Different studies have demonstrated that AMPs increase the permeability 50 
of the mycobacterial wall, which may facilitate the translocation of AMPs and other drugs across the 51 
membrane and into the cytoplasm. Additionally, acquisition of resistance to AMPs is very rare, and 52 
only a few bacteria show resistance. As a result, AMPs have promising clinical applications and the 53 
potential to combat mycobacterial infections [10-12]. 54 
The objective of the present study was to investigate the activity of 12 different AMPs (bactenecin, 55 
buforin I, mastoparan, indolicidin, histatin 5, histatin 8, magainin I, magainin II, cecropin PI, cecropin 56 
A, cecropin B and melittin) against clinical isolates of M. tuberculosis and M. avium using microtiter 57 
plates and the resazurin assay.  58 
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Six clinical isolates of M. tuberculosis susceptible to first-line anti-TB drugs and 4 clinical isolates 60 
of M. avium were studied. Two of the M. avium isolates were susceptible to clarithromycin, rifampicin 61 
and amikacin but resistant to ethambutol. The other 2 M. avium isolates were susceptible to 62 
clarithromycin, rifampicin amikacin and ethambutol. All of the isolates were obtained from the 63 
Laboratory of Microbiology of the Hospital Clínic of Barcelona (Barcelona, Spain).  64 
Of the 12 AMPs studied, histatin 5, magainin I, magainin II, cecropin PI, cecropin A and cecropin B 65 
were provided by Sigma-Aldrich (St. Louis, MO, USA). On the other hand, bactenecin, buforin I, 66 
mastoparan, indolicidin, histatin 8 and melittin were purchased from BionovaCientifica (S.L., 67 
Madrid, Spain) (Table 1) [12]. The lyophilized AMPs were dissolved in sterile distilled water and 68 
sterilized by filtration. Then, they were stored at -20°C in aliquots until use. All the AMPs were tested 69 
at concentrations ranging from 128 µg ml-1 to 0.125 µg ml-1. The AMPs were selected based on the 70 
activity shown against mycobacteria and other bacterial species described in previous studies as well 71 
as their availability and affordability [8].  72 
 73 
M. tuberculosis isolates were grown in Lowenstein-Jensen medium slants (Becton Dickinson, Sparks, 74 
MD) and M. avium isolates were grown in BDTM Columbia Agar with 5 % Sheep Blood plates 75 
(Becton Dickinson). Afterwards, all of the isolates were subcultured in Middlebrook 7H9 liquid 76 
medium (Becton Dickinson) supplemented with 10 % oleic acid-albumin-dextrose-catalase (OADC) 77 
(Comercial Bellés, Tarragona, Spain) and 0.25 % Tween 80 (Merck, Darmstadt, Germany) to avoid 78 
bacilli clump formation. After 7 days of incubation, M. tuberculosis cultures were subjected to 79 
disaggregation techniques by being vigorously vortexed in a tub containing glass beads (Sigma-80 
Aldrich) and the use of insulin syringes (Becton Dickinson). M. avium cultures were homogenised 81 
by agitation. Finally, the inoculum was adjusted to 1.5 x 108 cells ml-1 using a nephelometer 82 
(CrystalSpec™; Becton Dickinson).  83 
The minimum inhibitory concentration (MIC) of each peptide was determined using the resazurin 84 
assay in 96-well microtiter plates (Smartech Biosciences, Barcelona, Spain) as described by Palomino 85 
et al. [13]. Schena et al. [14] demonstrated that the resazurin assay is useful for the rapid and accurate 86 
MIC determination of delamanid in M. tuberculosis isolates, showing great concordance with the agar 87 
reference method. Briefly, 100 µl of Middlebrook 7H9 liquid media were added to each well. Then, 88 
serial dilutions of the AMPs ranging from 128 µg ml-1 to 0.125 µg ml-1 were made. Finally, 100 µl of 89 
inoculum at a final concentration of 5 x 105 cells ml-1 were added. Positive control wells consisted of 90 
100 µl of Middlebrook 7H9 and 100 µl of inoculum (5 x 105 cells ml-1). Negative control wells were 91 
prepared by adding 200 µl of Middlebrook 7H9. Plates were incubated at 37 °C in a 5 % CO2 92 
atmosphere for 7 days, after which 20 µl (10 % of the final volume) of fresh resazurin were added 93 
(alamarBlue® Invitrogen, Life Technologies, Belgium). Plates were covered with aluminium foil for 94 
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protection from light. After overnight incubation, visual reading was performed. Resazurin is a 95 
colorimetric reagent used to assess cell viability. This active agent, is blue in color and is reduced to 96 
resorufin (pink in color) by viable cells. A colorimetric change from blue to pink was interpreted as 97 
mycobacterial growth. The MIC was interpreted as the first concentration at which there was no 98 
colorimetric change. All the experiments were performed in duplicate for each isolate. 99 
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Twelve different AMPs were tested against clinical isolates of M. tuberculosis and M. avium. The 100 
AMPs tested showed moderate activity against M. tuberculosis and M. avium clinical isolates.  101 
The MIC values obtained are shown in Table 2. When tested against M. tuberculosis, mastoparan and 102 
melittin showed the best activity, with MIC values ranging from 32-64 µg ml-1. Indolicidin showed 103 
MIC values of 32 µg ml-1 against 2 of the isolates and of 64 µg ml-1 against 1 isolate. The other AMPs 104 
showed higher MICs (>128 µg ml-1).  105 
Regarding M. avium, indolicidin had the greatest activity with MIC values of 128 µg ml-1. All the 106 
remaining AMPs showed MICs >128 µg ml-1.   107 
To our knowledge, there are few studies on the in vitro effect of the AMPs investigated in the present 108 
study against M. tuberculosis, and especially against M. avium. Human neutrophil peptides (HNP) 109 
are the most frequently studied against mycobacteria [15]. Sharma et al. [16] reported that HNP-1 110 
has effective bactericidal activity against M. tuberculosis H37Rv in vitro as well as mycobacteria 111 
replicating within macrophages. Furthermore, Ogata et al. [17] demonstrated that HNP-1 and HNP-112 
2 killed all of the M. avium-M. intracellulare isolates. Therefore, the present study aimed to assess 113 
the antimicrobial activity of 12 AMPs with antibacterial activity against other bacteria in M. 114 
tuberculosis and M. avium clinical isolates. 115 
The activity of AMPs against mycobacteria is probably lower than in Gram-negative and other Gram-116 
positive bacteria [15]. In the present study, we tested a set of 12 AMPs previously tested against other 117 
bacteria but rarely studied or with unknown activity against mycobacteria. As shown in Table 2, 118 
mastoparan and melittin showed better results against M. tuberculosis than the other AMPs. In a 119 
previous study these two AMPs also showed a good activity against Acinetobacter baumanii [12]. 120 
However, these AMPs were less effective against the M. avium isolates. Differences in membrane 121 
composition may affect the activity of the AMPs. Therefore, we hypothesized that they may present 122 
a different efficacy in other mycobacterial species, suggesting that each AMP should be specifically 123 
tested in each species. Moreover, the mycobacterial cell membrane has a distinct architecture with a 124 
lipid-rich envelope, and taking into account the cationic and amphipathic nature of these peptides 125 
AMPs targeting mycobacterial membrane lipids could be further explored.  126 
Several AMPs have shown to cause membrane permeabilization, which would facilitate the entry of 127 
drugs into the mycobacterial cell and allow interaction with intracellular targets [18]. From this point 128 
of view, AMPs could have greater activity or even synergism when combined with antibiotics. 129 
Sharma et al. [19] observed that the bacterial peptide deformylase (PDF) showed synergism with 130 
isoniazid and rifampicin against M. tuberculosis H37Rv. Therefore, further studies are needed to 131 
stablish the potential synergism of any AMP in combination with antimycobacterial antibiotics [20]. 132 
Combination therapy including AMPs and common antibiotics would be an excellent therapeutic 133 
option to facilitate antibiotic uptake and decrease the MICs. Moreover, this novel treatment could 134 
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reduce the therapeutic dose, prevent the appearance of resistance and reduce side effects. In a recent 135 
study, Li et al. [21] demonstrated that the combination of PA-824 (pretomanid) and Cordyceps 136 
sinensis had greater bacteriostatic activity against M. tuberculosis than pretomanid alone.   137 
It is mandatory to find novel drugs with minimum or no toxicity to human cells. In general, many 138 
AMPs are considered to have low toxicity to eukaryotic cells. In addition, AMPs are cell selective, 139 
having the ability to kill bacterial cells without being toxic to human host cells. Furthermore, AMP 140 
selectivity could be increased by modifying the molecule, thus altering the physicochemical 141 
properties of the AMPs which would thereby enhance the safety profile [9, 7]. Nonetheless, some 142 
studies have described the in vitro cytotoxicity of some AMPs. For instance, Fu et al. [22] reported 143 
that HNP-1 exhibits important cytotoxicity to different types of cells when found at high 144 
concentrations. On the other hand, in order to improve their activity and to target AMPs to specific 145 
sites of infection, they could be loaded in drug-delivery systems such as liposomes and nanoparticles. 146 
These methods of drug administration reduce side effects by allowing the delivery of high drug 147 
concentrations directly to the site of infection.  However, this system of administration should be 148 
further optimized [7].  149 
In conclusion, AMPs are promising alternatives in the treatment of mycobacterial infections. 150 
Nonetheless, since the AMPs studied may exhibit even greater activity, further evaluation of these 151 
AMPs in combination and particularly associated with conventional antibiotics would be of great 152 
interest. Moreover, new methods of drug administration may improve the therapeutical potential of 153 
AMPs.  154 
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Sequence Length Source Activity 
Bactenecin RLCRIVVIRVCR 12 Bos taurus Antibacterial 
Buforin I AGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLLRKGNY 39 Bufo bufo gargarizans Antibacterial, Antifungal 
Mastoparan INLKALAALAKKIL 14 Vespula lewisii Antibacterial 
Indolicidin ILPWKWPWWPWRR 13 Bos taurus Antibacterial, Antifungal, Antiviral 
Histatin 5 DSHAKRHHGYKRKFHEKHHSHRGY 24 Homo sapiens Antibacterial, Antifungal, Antiviral 
Histatin 8 KFHEKHHSHRGY 12 Homo sapiens Antibacterial, Antifungal 
Magainin I GIGKFLHSAGKFGKAFVGEIMKS 23 Xenopus laevis Antibacterial, Antiviral 
Magainin II GIGKFLHSAKKFGKAFVGEIMNS 23 Xenopus laevis Antibacterial, Antifungal, Antiviral, Antiparasitic 
Cecropin PI SWLSKTAKKLENSAKKRISEGIAIAIQGGPR 31 Ascaris suum Antibacterial 
Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK 37 Hyalophora cecropia Antibacterial, Antiviral, Antiparasitic 
Cecropin B KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL 35 Antheraea pernyi Antibacterial, Antifungal 
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ 26 Apis mellifera Antibacterial, Antifungal, Antiviral, Antiparasitic 





Table 2. Minimum inhibitory concentrations of the 12 antimicrobial peptides tested against M. tuberculosis clinical isolates 
 
MICs, minimum inhibitory concentrations; Bac, bactenecin; Buf I, buforin I; Mas, mastoparan; Ind, indolicidin; His 5, histatin 5;  
His 8, histatin 8; Mag I, magainin I; Mag II, magainin II; Cec PI, cecropin PI; Cec A, cecropin A; Cec B, cecropin B; Mel, melittin. 
Isolate 
Antimicrobial peptide MICs (µg ml-1) 
Bac Buf I Mas Ind His 5 His 8 Mag I Mag II Cec PI Cec A Cec B Mel 
M. tuberculosis 1 >128 >128 64 >128 >128 >128 >128 >128 >128 >128 >128 64 
M. tuberculosis 2 >128 >128 64 >128 >128 >128 >128 >128 >128 >128 >128 64 
M. tuberculosis 3 >128 >128 64 >128 >128 >128 >128 >128 >128 >128 >128 64 
M. tuberculosis 4 >128 >128 32 32 >128 >128 >128 >128 >128 >128 >128 32 
M. tuberculosis 5 >128 >128 64 64 >128 >128 >128 >128 >128 >128 >128 64 
M. tuberculosis 6 >128 >128 32 32 >128 >128 >128 >128 >128 >128 >128 64 
